{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:49:08Z","timestamp":1795146548109,"version":"4.10.3"},"reference-count":75,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:p>\n                    Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is the leading cause of CKD worldwide. Although ESRD may be the most recognizable consequence of diabetic kidney disease, the majority of patients actually die from cardiovascular diseases and infections before needing kidney replacement therapy. The natural history of diabetic kidney disease includes glomerular hyperfiltration, progressive albuminuria, declining GFR, and ultimately, ESRD. Metabolic changes associated with diabetes lead to glomerular hypertrophy, glomerulosclerosis, and tubulointerstitial inflammation and fibrosis. Despite current therapies, there is large residual risk of diabetic kidney disease onset and progression. Therefore, widespread innovation is urgently needed to improve health outcomes for patients with diabetic kidney disease. Achieving this goal will require characterization of new biomarkers, designing clinical trials that evaluate clinically pertinent end points, and development of therapeutic agents targeting kidney-specific disease mechanisms (\n                    <jats:italic toggle=\"yes\">e.g.<\/jats:italic>\n                    , glomerular hyperfiltration, inflammation, and fibrosis). Additionally, greater attention to dissemination and implementation of best practices is needed in both clinical and community settings.Introduction\n                  <\/jats:p>","DOI":"10.2215\/cjn.11491116","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T20:50:20Z","timestamp":1495140620000},"page":"2032-2045","source":"Crossref","is-referenced-by-count":2770,"title":["Diabetic Kidney Disease"],"prefix":"10.2215","volume":"12","author":[{"given":"Radica Z.","family":"Alicic","sequence":"first","affiliation":[{"name":"Providence Health Care, Spokane, Washington;"},{"name":"University of Washington School of Medicine, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele T.","family":"Rooney","sequence":"additional","affiliation":[{"name":"Providence Health Care, Spokane, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Providence Health Care, Spokane, Washington;"},{"name":"University of Washington School of Medicine, Seattle, Washington;"},{"name":"Division of Nephrology, University of Washington School of Medicine, Seattle, Washington;"},{"name":"Institute of Translational Health Sciences, Seattle, Washington; and"},{"name":"Kidney Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"issue":"Suppl 10","key":"B1-20230813","first-page":"S75","article-title":"The discovery of diabetic nephropathy: From small print to centre stage","volume":"19","author":"Cameron","year":"2006","journal-title":"J Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mcna.2012.10.001","article-title":"Epidemiology of diabetic kidney disease","volume":"97","author":"Reutens","year":"2013","journal-title":"Med Clin North Am"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2011.861","article-title":"Temporal trends in the prevalence of diabetic kidney disease in the United States","volume":"305","author":"de Boer","year":"2011","journal-title":"JAMA"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1001\/jama.2015.10029","article-title":"Prevalence of and trends in diabetes among adults in the United States, 1988-2012","volume":"314","author":"Menke","year":"2015","journal-title":"JAMA"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/sj.ijo.0800541","article-title":"Overweight and obesity in the United States: Prevalence and trends, 1960-1994","volume":"22","author":"Flegal","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1001\/jama.2016.6458","article-title":"Trends in obesity among adults in the United States, 2005 to 2014","volume":"315","author":"Flegal","year":"2016","journal-title":"JAMA"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","article-title":"Chronic kidney disease: Global dimension and perspectives","volume":"382","author":"Jha","year":"2013","journal-title":"Lancet"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1681\/ASN.2012070739","article-title":"Renal lesions predict progression of diabetic nephropathy in type 1 diabetes","volume":"24","author":"Caramori","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/ki.1995.236","article-title":"Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial","volume":"47","year":"1995","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrneph.2010.55","article-title":"Metabolic memory and diabetic nephropathy: Potential role for epigenetic mechanisms","volume":"6","author":"Tonna","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dc13-2112","article-title":"The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: Overview","volume":"37","author":"Nathan","year":"2014","journal-title":"Diabetes Care"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1056\/NEJMoa1111732","article-title":"Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes","volume":"365","author":"de Boer","year":"2011","journal-title":"N Engl J Med"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"B21-20230813","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1464-5491.2008.02496.x","article-title":"Microvascular disease: What does the UKPDS tell us about diabetic nephropathy?","volume":"25","author":"Bilous","year":"2008","journal-title":"Diabet Med"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2337\/db05-1620","article-title":"Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74","volume":"55","author":"Retnakaran","year":"2006","journal-title":"Diabetes"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4103\/0971-4065.42336","article-title":"Thickness of glomerular and tubular basement membranes in preclinical and clinical stages of diabetic nephropathy","volume":"18","author":"Tyagi","year":"2008","journal-title":"Indian J Nephrol"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2337\/diabetes.51.5.1580","article-title":"The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes","volume":"51","author":"Drummond","year":"2002","journal-title":"Diabetes"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1034\/j.1600-0463.2001.d01-142.x","article-title":"Renal structures in type 2 diabetic patients with elevated albumin excretion rate","volume":"109","author":"Osterby","year":"2001","journal-title":"APMIS"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/ki.1988.193","article-title":"Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions","volume":"34","author":"Saito","year":"1988","journal-title":"Kidney Int"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0046-8177(93)90066-P","article-title":"Focal mesangiolysis and the pathogenesis of the Kimmelstiel-Wilson nodule","volume":"24","author":"Stout","year":"1993","journal-title":"Hum Pathol"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00125-008-1051-7","article-title":"The kidney in diabetes: Dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007","volume":"51","author":"Fioretto","year":"2008","journal-title":"Diabetologia"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 2","key":"B34-20230813","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diab.32.2.S64","article-title":"The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy","volume":"32","author":"Mogensen","year":"1983","journal-title":"Diabetes"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/ndt\/gfh470","article-title":"Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria","volume":"19","author":"Gaede","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"B37-20230813","article-title":"Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD-Annals initiative [published online ahead of print December 9, 2016]","author":"Pacilli","journal-title":"Diabetes Metab Res Rev"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.kint.2016.01.023","article-title":"An autopsy study suggests that diabetic nephropathy is underdiagnosed","volume":"90","author":"Klessens","year":"2016","journal-title":"Kidney Int"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00125-006-0215-6","article-title":"Anaemia in diabetes: Is there a rationale to TREAT?","volume":"49","author":"Thomas","year":"2006","journal-title":"Diabetologia"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/MED.0b013e328350a6e1","article-title":"Type 2 diabetes and bone fractures","volume":"19","author":"Moseley","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1681\/ASN.2009030282","article-title":"Why is the mortality of dialysis patients in the United States much higher than the rest of the world?","volume":"20","author":"Foley","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.1992.274","article-title":"Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes","volume":"42","author":"Tuttle","year":"1992","journal-title":"Kidney Int"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1056\/NEJM199106063242304","article-title":"Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus","volume":"324","author":"Tuttle","year":"1991","journal-title":"N Engl J Med"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1152\/ajprenal.00155.2001","article-title":"Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes","volume":"282","author":"Tuttle","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"F473","DOI":"10.1152\/ajprenal.00503.2013","article-title":"The physical basis of renal fibrosis: Effects of altered hydrodynamic forces on kidney homeostasis","volume":"306","author":"Grabias","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B48-20230813","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.diabet.2014.10.003","article-title":"The impact of hyperfiltration on the diabetic kidney","volume":"41","author":"Premaratne","year":"2015","journal-title":"Diabetes Metab"},{"key":"B49-20230813","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: Glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"B50-20230813","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"issue":"Suppl 1","key":"B51-20230813","first-page":"S4","article-title":"Standards of medical care in diabetes-2016: Summary of revisions","volume":"39","year":"2016","journal-title":"Diabetes Care"},{"key":"B52-20230813","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: A report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care"},{"key":"B53-20230813","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B54-20230813","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"B55-20230813","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"B56-20230813","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"B57-20230813","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/ki.2014.296","article-title":"Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes","volume":"87","author":"Papademetriou","year":"2015","journal-title":"Kidney Int"},{"key":"B58-20230813","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"B59-20230813","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"B60-20230813","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"B61-20230813","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"B62-20230813","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"B63-20230813","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"B64-20230813","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"B65-20230813","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMe1513301","article-title":"Redefining blood-pressure targets--SPRINT starts the marathon","volume":"373","author":"Perkovic","year":"2015","journal-title":"N Engl J Med"},{"key":"B66-20230813","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"B67-20230813","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.kint.2015.12.024","article-title":"A SPRINT to the finish, or just the beginning? Implications of the SPRINT results for nephrologists","volume":"89","author":"Rocco","year":"2016","journal-title":"Kidney Int"},{"key":"B68-20230813","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.2337\/diacare.28.11.2686","article-title":"The effect of ruboxistaurin on nephropathy in type 2 diabetes","volume":"28","author":"Tuttle","year":"2005","journal-title":"Diabetes Care"},{"key":"B69-20230813","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"B70-20230813","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: The PREDIAN trial","volume":"26","author":"Navarro-Gonz\u00e1lez","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B71-20230813","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1681\/ASN.2013080830","article-title":"The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy","volume":"25","author":"de Zeeuw","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B73-20230813","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B74-20230813","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"B75-20230813","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B76-20230813","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B77-20230813","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B78-20230813","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"B80-20230813","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"B82-20230813","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11892-013-0381-0","article-title":"Uric acid lowering to prevent kidney function loss in diabetes: The preventing early renal function loss (PERL) allopurinol study","volume":"13","author":"Maahs","year":"2013","journal-title":"Curr Diab Rep"},{"key":"B83-20230813","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"B84-20230813","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/dc16-0621","article-title":"Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial","volume":"40","author":"Mosenzon","year":"2017","journal-title":"Diabetes Care"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201712000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:50Z","timestamp":1786369010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201712000-00017"}},"subtitle":["Challenges, Progress, and Possibilities"],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.11491116","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}